Tscan Therapeutics Stock Forward View
| TCRX Stock | USD 1.02 0.02 1.92% |
Tscan Stock outlook is based on your current time horizon.
At this time, the RSI of Tscan Therapeutics' share price is approaching 43. This usually implies that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Tscan Therapeutics, making its price go up or down. Momentum 43
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.32) | EPS Estimate Current Year (1.24) | EPS Estimate Next Year (1.00) | Wall Street Target Price 6 | EPS Estimate Current Quarter (0.33) |
Using Tscan Therapeutics hype-based prediction, you can estimate the value of Tscan Therapeutics from the perspective of Tscan Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
Tscan Relative Strength Index
The Naive Prediction forecasted value of Tscan Therapeutics on the next trading day is expected to be 0.91 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.81.Tscan Therapeutics Hype to Price Pattern
Investor biases related to Tscan Therapeutics' public news can be used to forecast risks associated with an investment in Tscan. The trend in average sentiment can be used to explain how an investor holding Tscan can time the market purely based on public headlines and social activities around Tscan Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Tscan Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Tscan Therapeutics.
The Naive Prediction forecasted value of Tscan Therapeutics on the next trading day is expected to be 0.91 with a mean absolute deviation of 0.05 and the sum of the absolute errors of 2.81. Tscan Therapeutics after-hype prediction price | USD 1.04 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Tscan Therapeutics to cross-verify your projections. Tscan Therapeutics Additional Predictive Modules
Most predictive techniques to examine Tscan price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Tscan using various technical indicators. When you analyze Tscan charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Forecasting cash, or other financial indicators, requires analysts to apply different statistical methods, techniques, and algorithms to find hidden patterns within the Tscan Therapeutics' financial statements to predict how it will affect future prices.
Cash | First Reported 2019-12-31 | Previous Quarter 169.4 M | Current Value 169.5 M | Quarterly Volatility 60.8 M |
Tscan Therapeutics Naive Prediction Price Forecast For the 31st of January
Given 90 days horizon, the Naive Prediction forecasted value of Tscan Therapeutics on the next trading day is expected to be 0.91 with a mean absolute deviation of 0.05, mean absolute percentage error of 0, and the sum of the absolute errors of 2.81.Please note that although there have been many attempts to predict Tscan Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Tscan Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Tscan Therapeutics Stock Forecast Pattern
| Backtest Tscan Therapeutics | Tscan Therapeutics Price Prediction | Buy or Sell Advice |
Tscan Therapeutics Forecasted Value
In the context of forecasting Tscan Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Tscan Therapeutics' downside and upside margins for the forecasting period are 0.01 and 5.91, respectively. We have considered Tscan Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Tscan Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Tscan Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.297 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0461 |
| MAPE | Mean absolute percentage error | 0.0437 |
| SAE | Sum of the absolute errors | 2.8125 |
Predictive Modules for Tscan Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tscan Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Tscan Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Tscan Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Tscan Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Tscan Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Tscan Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Tscan Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Tscan Therapeutics' historical news coverage. Tscan Therapeutics' after-hype downside and upside margins for the prediction period are 0.05 and 6.04, respectively. We have considered Tscan Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Tscan Therapeutics is abnormally volatile at this time. Analysis and calculation of next after-hype price of Tscan Therapeutics is based on 3 months time horizon.
Tscan Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Tscan Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tscan Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Tscan Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.17 | 5.00 | 0.01 | 0.01 | 10 Events / Month | 6 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.02 | 1.04 | 0.00 |
|
Tscan Therapeutics Hype Timeline
Tscan Therapeutics is at this time traded for 1.02. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.01. Tscan is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at -0.17%. %. The volatility of related hype on Tscan Therapeutics is about 9433.96%, with the expected price after the next announcement by competition of 1.01. About 74.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Tscan Therapeutics recorded a loss per share of 1.12. The entity last dividend was issued on the 13th of September 1970. Given the investment horizon of 90 days the next projected press release will be in about 10 days. Check out Historical Fundamental Analysis of Tscan Therapeutics to cross-verify your projections.Tscan Therapeutics Related Hype Analysis
Having access to credible news sources related to Tscan Therapeutics' direct competition is more important than ever and may enhance your ability to predict Tscan Therapeutics' future price movements. Getting to know how Tscan Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Tscan Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ACRV | Acrivon Therapeutics Common | (0.36) | 6 per month | 7.62 | 0.01 | 8.21 | (9.09) | 66.02 | |
| RLMD | Relmada Therapeutics | (0.06) | 8 per month | 3.84 | 0.17 | 10.95 | (8.60) | 36.80 | |
| LITS | Lite Strategy | (0.06) | 5 per month | 0.00 | (0.1) | 7.73 | (9.52) | 26.34 | |
| ACET | Adicet Bio | 0.19 | 6 per month | 0.00 | (0.18) | 6.18 | (7.60) | 16.66 | |
| IMUX | Immunic | (0.05) | 7 per month | 0.00 | (0.07) | 9.43 | (6.58) | 21.44 | |
| PMVP | Pmv Pharmaceuticals | (0.03) | 8 per month | 0.00 | (0.16) | 5.98 | (4.65) | 13.80 | |
| VXRT | Vaxart Inc | 0.01 | 10 per month | 5.87 | 0.13 | 15.15 | (5.41) | 75.42 | |
| NTRB | Nutriband | (0.15) | 10 per month | 0.00 | (0.13) | 9.04 | (7.23) | 32.02 | |
| XBIT | XBiotech | (0.08) | 8 per month | 3.36 | 0 | 6.67 | (5.88) | 28.09 | |
| FBIO | Fortress Biotech | 0.06 | 11 per month | 3.90 | 0.11 | 6.63 | (5.51) | 29.21 |
Other Forecasting Options for Tscan Therapeutics
For every potential investor in Tscan, whether a beginner or expert, Tscan Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Tscan Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Tscan. Basic forecasting techniques help filter out the noise by identifying Tscan Therapeutics' price trends.Tscan Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tscan Therapeutics stock to make a market-neutral strategy. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Tscan Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Tscan Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Tscan Therapeutics shares will generate the highest return on investment. By undertsting and applying Tscan Therapeutics stock market strength indicators, traders can identify Tscan Therapeutics entry and exit signals to maximize returns.
Tscan Therapeutics Risk Indicators
The analysis of Tscan Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Tscan Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting tscan stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.21 | |||
| Standard Deviation | 6.69 | |||
| Variance | 44.8 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Tscan Therapeutics
The number of cover stories for Tscan Therapeutics depends on current market conditions and Tscan Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Tscan Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Tscan Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Tscan Therapeutics Short Properties
Tscan Therapeutics' future price predictability will typically decrease when Tscan Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Tscan Therapeutics often depends not only on the future outlook of the potential Tscan Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tscan Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 112 M | |
| Cash And Short Term Investments | 290.1 M |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.